Global AI in Bioinformatics Market Outlook 2025-2035
The global AI in bioinformatics market is witnessing transformative growth driven by increasing adoption of advanced artificial intelligence technologies in genomics, drug discovery, and other omics applications. AI tools are revolutionizing biological data analysis, accelerating research, and enabling breakthroughs in personalized medicine. Integration of machine learning, deep learning, and data mining, along with expanding cloud solutions, is bolstering market growth across both developed and emerging regions.
Latest Market Dynamics
Key Drivers
- Rising demand for personalized medicine and genomics data analysis is propelling market expansion. For instance, Illumina’s AI-empowered genomics platforms have significantly enhanced speed and accuracy of genetic sequencing in 2025.
- Continuous advancements in AI algorithms—exemplified by NVIDIA’s launch of AI-powered computing infrastructure for bioinformatics in early 2025—are enhancing data processing capabilities and supporting complex bioinformatics workflows.
Key Trends
- Integration of cloud-based AI bioinformatics platforms enabling global collaboration. Google’s Verily Life Sciences launched new cloud genomics analytics in June 2024, expanding real-time data access for researchers.
- Automated drug discovery gaining traction, as shown by BenevolentAI’s 2025 use of advanced deep learning systems to identify new therapeutic candidates, reducing time-to-market for novel drugs.
Key Opportunities
- Expansion of AI solutions to emerging markets—DNAnexus announced strategic partnerships in South-East Asia during July 2024, tapping into untapped genomic research landscapes.
- Collaboration between bioinformatics leaders and AI technology firms, as IBM and Thermo Fisher Scientific announced a co-developed AI-powered platform for multi-omics research in August 2024.
Key Challenges
- High complexity and heterogeneity of bioinformatics datasets remain a challenge—Agilent Technologies addressed this with improved automated AI data pre-processing tools released in June 2024.
- Talent shortage in AI-driven bioinformatics skill sets. Sophia Genetics invested in workforce training programs to mitigate this in late 2024.
Key Restraints
- Stringent regulatory frameworks slowing AI adoption in sensitive healthcare sectors, as seen in Qiagen’s delayed launch of AI-enabled diagnostic solutions due to EU data compliance in July 2024.
- Data privacy and security concerns remain, with Microsoft implementing advanced encryption for its AI bioinformatics cloud platform in September 2024 to address industry apprehension.
Market Share by Type, 2025
In 2025, Software dominates the AI in bioinformatics market by type, encompassing a diverse suite of AI-driven analysis and visualization tools. Services follow as organizations outsource complex integration, training, and support needs. Hardware, including GPUs and AI accelerators, supports the underlying computational demand. The ongoing digital transformation in healthcare and research fuels the reliance on innovative software and hardware combinations, while platforms and specialized tools continue gaining preference for tailored applications.
Market Share by Application, 2025
Genomics accounts for the highest share of AI in bioinformatics applications by 2025, leveraging AI to unlock insights from massive genomic datasets. Chemoinformatics & Drug Design is the second largest segment, fueled by the surge in AI-driven drug discovery initiatives. Transcriptomics rounds out the top three, reflecting growing interest in gene expression studies. The emergence of AI models capable of integrating and interpreting multi-omics data is a significant market growth driver.
Market Revenue (USD Million), 2020–2035
The global AI in bioinformatics market revenue is projected to rise substantially from $2,800 million in 2020 to approximately $19,500 million by 2035. The adoption curve accelerates post-2025, with annualized growth seen across all regions and market segments. Robust investments in genomics and personalized medical research, alongside continuous improvements in AI technologies, underpin this upward trajectory.
Market YOY Growth (%), 2020–2035
Year-over-year growth in the AI in bioinformatics market peaks at 19.5% in 2025 during the immediate post-pandemic period of accelerated adoption and then stabilizes at a CAGR around 11% through 2035 as the technology matures and market penetration deepens globally.
Regional Market Share by Region, 2025
North America leads the global AI in bioinformatics market in 2025, attributed to robust R&D funding, AI innovation, and presence of leading biotech firms. APAC demonstrates significant growth, propelled by increasing biotech investments and genomics projects in China and India. Europe retains a strong share with a focus on collaborative research and regulatory advancements. These regions are set to shape AI-driven bioinformatics innovation and application throughout the forecast period.
Market Players Share (%), 2025
Illumina, Thermo Fisher Scientific, and DNAnexus emerge as the top market players by share in 2025. Illumina’s dominance is linked to its comprehensive bioinformatics software ecosystem, while Thermo Fisher’s robust genomics and AI solutions fuel its substantial presence. DNAnexus stands out for its secure, scalable cloud platform supporting AI-powered research collaborations.
Market Buyers Share (%), 2025
Pharmaceutical companies are the primary buyers of AI in bioinformatics solutions, holding the greatest market share in 2025 due to extensive investment in drug discovery and development. Academic and research institutes also represent a significant share, followed by healthcare providers adopting AI for advanced diagnostics and patient care.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 5800 |
| Regions | North America, Europe, APAC, South America, Middle East, Africa |
| Segments | By Type (Software, Services, Hardware, Platform, Tools, Others), By Application (Genomics, Chemoinformatics & Drug Design, Transcriptomics, Proteomics, Metabolomics, Others), By Distribution Channels (Direct Sales, Distributors, Online Sales, Resellers, Marketplace, Others), By Technology (Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Data Mining, Others), By Organization Size (Small, Medium, Large) |
| Players | Illumina, Thermo Fisher Scientific, IBM, Microsoft, DNAnexus, Sophia Genetics, Biomax Informatics, NVIDIA Corporation, Deep Genomics, BenevolentAI, Google (Verily Life Sciences), Genedata, Qiagen, Agilent Technologies, Seven Bridges Genomics |
Key Recent Developments
- June 2024: Verily Life Sciences launches an AI-powered cloud genomics platform to facilitate cross-border research collaboration.
- July 2024: DNAnexus forges strategic partnerships to expand AI-enabled bioinformatics services in Southeast Asia.
- August 2024: IBM and Thermo Fisher Scientific announce a joint AI platform for multi-omics research analytics.
- September 2024: Microsoft integrates new security technologies into its AI bioinformatics cloud offering to enhance data privacy.
- October 2024: Agilent Technologies unveils automated AI-driven data pre-processing solutions for large-scale genomic research.
